Latest Biotech News

Pfizer struck a licensing and collaboration deal giving it global rights to a once‑daily oral GLP‑1 small molecule from Yaopharma (Fosun subsidiary), paying $150 million upfront as part of a...

Novartis inked a multi‑program, strategic collaboration with Relation Therapeutics worth up to $1.7 billion to discover and develop targets for atopic and other immune‑driven dermatologic...

Insilico Medicine published preclinical data for an AI‑designed PROTAC degrader targeting PKMYT1, demonstrating on‑target activity in cell lines and xenografts guided by generative Chemistry42...

Amplifold closed a €5 million seed round to commercialize DNA origami‑based signal amplification for lateral flow assays (LFAs). The Munich spinout says its nanostructures can increase LFA...

Radboud University Medical Center launched long‑read whole‑genome sequencing (WGS) using Pacific Biosciences technology as a frontline diagnostic test for genetic eye disease and severe...

Roche disclosed interim adjuvant data showing its oral selective estrogen receptor degrader (SERD) reduced the risk of invasive disease recurrence or death by about 30% versus standard of care....

The FDA’s Center for Biologics Evaluation and Research (CBER) signaled a policy shift: most chimeric antigen receptor (CAR‑T) cell therapy approvals will now be supported by randomized controlled...

Eli Lilly announced Huntsville, Alabama, as the site for a $6 billion active pharmaceutical ingredient (API) facility that will support peptide and small‑molecule medicines including its oral...

Pfizer continued to expand its obesity portfolio with two separate deals for oral GLP‑1 candidates from China: a $150 million upfront license for YaoPharma’s once‑daily oral GLP‑1 and a broader $2...

Mirum Pharmaceuticals agreed to acquire Bluejay Therapeutics in a deal valuing the transaction at roughly $820 million, bringing brelovitug, a late‑stage monoclonal antibody for chronic hepatitis...

Kelonia Therapeutics reported early clinical data showing efficacy for its in‑vivo CAR‑T approach in multiple myeloma, with single‑infusion results producing deep responses in a small cohort. The...

Pow.Bio and the Bühler Group said they are ready to market an integrated continuous precision fermentation platform that combines Pow.Bio’s AI‑enabled continuous fermentation technology with...

Radboud University Medical Center has deployed Pacific Biosciences long‑read whole‑genome sequencing (WGS) as a frontline diagnostic test for selected genetic indications, replacing a basket of...

Ginkgo Bioworks and AI drug‑discovery firm Deep Origin lead a multi‑partner consortium that secured up to $31.7 million from ARPA‑H to develop non‑animal models for drug safety and ADME‑Tox...

Dyne Therapeutics announced that its Duchenne muscular dystrophy candidate met the primary endpoint in a pivotal study, positioning the company to pursue accelerated approval with the U.S. FDA....

The FDA signaled a policy shift by saying it will generally require randomized controlled trials (RCTs) to support approvals of CAR‑T cell therapies, except in narrowly defined circumstances such...

Late‑breaking results from the Majestec‑3 trial showed the teclistamab plus daratumumab combination produced an 83.4% three‑year progression‑free survival (PFS) rate versus 29.7% for standard...

Mirum Pharmaceuticals agreed to acquire Bluejay Therapeutics in a cash‑and‑stock deal to add brelovitug, a late‑stage monoclonal antibody for chronic hepatitis D virus (HDV), to its rare‑liver...

Eli Lilly selected Huntsville, Alabama, as the site for a $6 billion active pharmaceutical ingredient (API) plant focused on peptide and small‑molecule medicines, including the oral GLP‑1...

Insilico Medicine reported the AI‑generated discovery of a bifunctional PROTAC degrader targeting PKMYT1, with preclinical activity in biomarker‑selected cancer models; the work was detailed in...